Gene-Eden-VIR is Antiviral: Results of a Post Marketing Clinical Study

Polansky, H., Itzkovitz, E. The Center for the Biology of Chronic Disease, Rochester, NY 14620

Abstract

Introduction: This paper reports the results of a post marketing clinical study that tested the effect of Gene-Eden-VIR on viral infections. Specifically, the study tested the effect of Gene-Eden-VIR on the severity, duration, and frequency of symptoms associated with the Human Papillomavirus (HPV), Herpes Simplex Virus (HSV), Epstein Barr Virus (EBV), Human Cytomegalovirus (HCMV), or Hepatitis C Virus (HCV). The symptoms included abnormal Pap smear, low and high grade cervical dysplasia, warts, blisters, cold sores, hives, skin tabs, panic attacks, depression, kidney problems, sleeping problems, liver problems, fever, fatigue, sore throat, swollen lymph nodes, diarrhea, and weight loss.

Treatment: A capsule of Gene-Eden-VIR includes 100 mg of quercetin, 150 mg of camellia sinesis extract, 50 mg of a cinnamomum extract, 25 mg of a licorice extract, and 100 mcg of selenium. The treatment included 1, 2, 3, or 4 capsules per day, for 2 to 54 weeks.

Population: 60 infected individuals, ages 20 to 66.

Results: The participants reported no side effects from Gene-Eden-VIR. Seventy three percent of the individuals treated with Gene-Eden-VIR reported a decrease in their symptoms. Specifically, they report a decrease in the severity of their symptoms (p<0.001), the duration of their symptoms (p<0.001), the frequency of their symptoms (p<0.001). During treatment with Gene-Eden-VIR, the participants also reported an increase in their physical strength (p<0.001), their energy levels (p<0.001), their concentration (p<0.001), and their general health (p<0.001). The participants also reported a duration effect (p<0.001), that is, those treated with Gene-Eden-VIR for a longer time report a larger decrease in their symptoms. The research showed no interviewer bias, no selection bias, and a surprising response shift. The research also showed that Gene-Eden-VIR has therapeutic consistency under varying manufacturing conditions.

Conclusions: Our post marketing clinical study showed that Gene-Eden-VIR is a safe and effective treatment against the Human Papillomavirus (HPV), Herpes Simplex Virus (HSV), Epstein Barr Virus (EBV), Human Cytomegalovirus (HCMV), or Hepatitis C Virus (HCV).

Note: If you would like to read the full paper, please send an email to the Center for the Biology of Chronic Disease (CBCD) requesting a copy.

Click Gene-Eden-VIR to see the website of Gene-Eden-VIR that includes information for the general public.